1622P A Phase II Study of the First-in-class Oral Innate Immune Activator BXCL701 with Pembrolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer (mcrpc): Long-term Follow-Up
Annals of Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined